Is C4 Therapeutics, Inc. (CCCC) a Buy, Sell, or Hold?
C4 Therapeutics, Inc.
NASDAQ:CCCC
$3.765 USD
-$0.04 (-1.18%)
- Volume
- 888.62K
- Average Volume
- 3.1M
- Market Capitalization
- $311.84M
- P/E Ratio
- -3.16
- Dividend Yield
- 0.00%
- Price Target
- $7.00
- Year High
- $5.17
- Year Low
- $1.69
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $9.00
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Andrew J. Hirsch |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CCCC |
| CUSIP | 12529R107 |
| CIK | 0001662579 |
| Web | https://www.c4therapeutics.com |
| Phone | 617 231 0700 |
| Currency | USD |
| Employees | 104 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.25 |
| Payout Ratio | 0.00 |
| Current Ratio | 9.00 |
| Quick Ratio | 9.00 |
| Cash Ratio | 2.25 |
Sales & Book Value
| Annual Sales | $35.95M |
| Price / Sales | 8.95 |
| Cash Flow | -0.76 |
| Price / Cash Flow | -3.25 |
| Price / Book | 2.03 |
Price Target and Rating
| Average Stock Price Forecast | $7.00 |
| High Stock Price Forecast | $7.00 |
| Low Stock Price Forecast | $7.00 |
| Forecast Upside/Downside | -46.21% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 14 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.27 |
| Trailing P/E Ratio | -3.16 |
| PEG Ratio | -0.19 |
| P/E Growth | -0.19 |
| Net Income | $-104.99M |
| Net Margin | -297.76% |
| Pretax Margin | -297.41% |
| Return on Equity | -50.68% |
| Return on Assets | -31.56% |
Financials Score
| AltmanZ Score | -1.33 |
| Piotroski Score | 3.00 |
| Working Capital | 218.12M |
| Total Assets | 328.86M |
| Ebit | -103.68M |
| Market Cap | 324.68M |
| Total Liabilities | 94.61M |
Poll Results
About C4 Therapeutics, Inc. (NASDAQ:CCCC) Stock
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various non-Hodgkin lymphomas, such as peripheral T-cell lymphoma and mantle cell lymphoma. Additionally, C4 Therapeutics is advancing several other programs: CFT8634, an orally bioavailable BiDAC degrader targeting the BRD9 protein, for potential use in synov ... ial sarcoma and SMARCB1-deleted solid tumors. CFT1946, an orally administered BiDAC degrader designed to act on the V600X mutant BRAF, aimed at indications like melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally available, allosteric, and mutant-selective BiDAC degrader specifically targeting epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. Their early-stage pipeline also features RET degraders for various forms of cancer. C4 Therapeutics, Inc. has formed strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. The company was established in 2015 and its headquarters are located in Watertown, Massachusetts.
Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?
2026-07-07 10:41:25
Here is how C4 Therapeutics, Inc. (CCCC) and Illumina (ILMN) have performed compared to their sector so far this year.
C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know
2026-07-03 13:00:37
Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.
2026-06-18 14:02:18
C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide Transcript
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
2026-06-18 10:41:12
Here is how C4 Therapeutics, Inc. (CCCC) and Clene Inc. (CLNN) have performed compared to their sector so far this year.
2026-06-11 07:00:00
At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status
C4 Therapeutics "Buy" On Cemsidomide Advancement And Competitor's Positive Readout
2026-06-02 10:58:12
I initiate C4 Therapeutics (CCCC) with a "Buy rating," driven by robust progress of its next-gen CELMoD cemsidomide in relapsed/refractory multiple myeloma. Company's lead program advances through phase 2 MOMENTUM and phase 1b combination studies, with key data catalysts expected at EHA 2026 and throughout 2026–2027. Strong financial position with $268.3M cash as of March 2026 supports operations into 2028, enabling continued pipeline expansion and clinical execution.
C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?
2026-06-01 13:02:11
C4 Therapeutics (CCCC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
C4 Therapeutics to Participate in Upcoming Conferences
2026-05-20 07:00:00
WATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in the upcoming conferences.
Frequently Asked Questions
-
What is the current C4 Therapeutics, Inc. (CCCC) stock price?
-
C4 Therapeutics, Inc.(NASDAQ:CCCC) stock price is $3.765 in the last trading session. During the trading session, CCCC stock reached the peak price of $5.17 while $1.69 was the lowest point it dropped to. The percentage change in CCCC stock occurred in the recent session was --1.18% while the dollar amount for the price change in CCCC stock was -$-0.04.
-
CCCC's industry and sector of operation?
-
The NASDAQ listed CCCC is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CCCC?
-
Nathanael S. Gray | Co-Founder & Member of Scientific Advisory Board
Leonard J. Reyno | Chief Medical Officer
Courtney Solberg | Senior Manager of Investor Relations
Kelly Schick | Chief People Officer
Paige Mahaney | Chief Scientific Officer -
How many employees does CCCC have?
-
Number of CCCC employees currently stands at 104. CCCC operates from 490 Arsenal Way, Watertown, MA 02472, US.
-
Link for CCCC official website?
-
Official Website of CCCC is: https://www.c4therapeutics.com
-
How do I contact CCCC?
-
CCCC could be contacted at phone #617 231 0700 and can also be accessed through its website. CCCC operates from 490 Arsenal Way, Watertown, MA 02472, US.
-
How many shares of CCCC are traded daily?
-
The average number of CCCC shares traded daily for last 3 months was 3.1M.
-
What is the market cap of CCCC currently?
-
The market value of CCCC currently stands at $311.84M with its latest stock price at $3.765